Post-Hoc Analyses Support Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Uncontrolled Eosinophilic Asthma and Prior Exacerbations. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 1, p. s524, 2025. DOI: 10.25251/skin.9.supp.524. Disponível em: https://skin.dermsquared.com/skin/article/view/3148. Acesso em: 17 feb. 2026.